• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Dyne Therapeutics Inc (NQ: DYN )

    24.73 +1.04 (+4.39%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 616,906
    Open 23.79
    Bid (Size) 24.31 (1)
    Ask (Size) 27.60 (15)
    Prev. Close 23.69
    Today's Range 23.50 - 25.12
    52wk Range 6.400 - 30.27
    Shares Outstanding 58,310,703
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +89.36%
    +89.36%
    1 Month
    -13.23%
    -13.23%
    3 Month
    +16.87%
    +16.87%
    6 Month
    +273.56%
    +273.56%
    1 Year
    +143.65%
    +143.65%

    More News

    Read More
    Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Recap: Dyne Therapeutics Q4 Earnings
    Via Benzinga
    Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Dyne Therapeutics Announces CEO Transition
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
    Via Benzinga
    Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Chardan Capital Maintains Buy Rating for Dyne Therapeutics: Here's What You Need To Know
    Via Benzinga
    Piper Sandler Maintains Overweight Rating for Dyne Therapeutics: Here's What You Need To Know
    Via Benzinga
    DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q4 2023
    Via InvestorPlace
    Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Top 4 Health Care Stocks You May Want To Dump In February
    Via Benzinga
    Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Dyne Therapeutics to Present at February Investor Conferences
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    7 Speculative Stocks to Double Your Money THIS Year
    Via InvestorPlace
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    $30M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
    Via Benzinga
    Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Crude Oil Moves Lower; Walgreens Posts Upbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.